Protein degradation targeting chimera molecule and application thereof
By developing a protein-degrading chimeric molecule that can combine IRAK kinase and E3 ubiquitin ligase, targeted degradation is solved, and the problem of low degradation efficiency of IRAK kinase in the prior art has been solved, and IRAK4 and Efficient and selective degradation of IRAK1 provides an effective way to treat IRAK activity-related diseases.
Patent Information
- Application Number
- CN202411207411.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-29
AI Technical Summary
The prior art is difficult to effectively degrade and regulate IRAK kinase, resulting in challenges in the treatment of diseases such as inflammatory diseases and tumors.
Develop a protein-degradable chimera molecule, which uses the ubiquitin-proteasome system to perform targeted degradation by combining IRAK kinase and E3 ubiquitin ligase, and achieves efficient and selective degradation of IRAK4 and/or IRAK1.
Significantly degrading IRAK kinases and blocking IRAK-dependent proinflammatory signaling provides potential solutions for the treatment of IRAK activity-related diseases with high efficiency and selectivity.
Smart Images

Figure CN119039379A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicines and relates to a protein degradation targeted chimera molecule and application thereof. Background Art
[0002] Protein kinases are enzyme proteins widely present in cells and on the cell surface. So far, nearly 600 protein kinases have been discovered and identified. They belong to a structurally related protein family, and their known members are related to almost all cell signal transduction activities. The catalytic function of protein kinase is to transfer the γ-phosphate group in the ATP molecule to the specific threonine, serine or tyrosine group of the target protein, so that the conformation of the target protein changes, resulting in the function of the target protein changing from a static state to an activated state. The signal transduction and regulation involved in protein kinases play an extremely important role in the normal function of cells and organs, including cell growth, differentiation, proliferation, angiogenesis, apoptosis, cytoskeleton arrangement, regulation of metabolic reactions, membrane transport and cell movement. In addition, the non-catalytic functions of protein kinases also play an indispensable role, including allosteric effects, subcellular targeting, protein complex scaffolds, protein competitive interactions and DNA binding. On the other hand, if gene mutations or overexpression of protein kinases occur, dysregulated protein kinases can lead to a variety of pathological changes, including cancer, inflammation, autoimmune diseases, cardiovascular and nervous system diseases.
[0003] Interleukin-1 receptor-associated kinase (IRAK) refers to a class of serine / threonine kinases that can bind to interleukin-1 receptor (IL-1R) under the induction of pro-inflammatory cytokine interleukin-1 (IL-1). It plays an important role in regulating the intracellular signal transduction network that controls inflammation. Currently, IRAK1, IRAK2, IRAK3 (also known as IRAK-M) and IRAK4 are known. The four members of the IRAK family all have a kinase domain (KD) containing serine and threonine and a conserved death domain (DD). Except for IRAK4, the other three IRAK kinases have a long C-terminal structure (C-terminal domain). Among them, IRAK1 and IRAK4 play a positive regulatory role in the Toll-like receptor (TLR)-mediated signaling pathway, while IRAK2 and IRAK3 play a negative regulatory role in the TLR-mediated signaling pathway. IRAK4 has both kinase activity and scaffold function, and is considered to be the first protein kinase activated downstream of the IL-1 receptor and all TLRs except TLR3. It initiates signal transduction in the innate immune system through the rapid activation of IRAK1 and the slower activation of IRAK2, activating the downstream NF-κB and JNK signaling pathways, and plays an important role in human inflammatory responses and tumors. Therefore, the IRAK family has broad prospects for clinical application and can serve as an effective potential target for the treatment of various autoimmune diseases and tumor diseases.
[0004] Targeted protein degradation (TPD) is an emerging technology in the field of small molecule drug design. It can use the cell's own protein degradation mechanism to regulate the activity and abundance of specific proteins in the body, and overcome diseases by targeting the degradation of pathogenic proteins, providing a new strategy for the treatment of a variety of diseases including cancer and neurodegenerative diseases. Compared with traditional small molecule inhibitors, TPD drugs do not need to rely on active sites on proteins to work, and have potential advantages in terms of dosage, side effects, and targeting "non-drugable" proteins. It can also overcome the drug resistance of existing small molecule inhibitors and greatly expand the range of druggable targets. Protein degradation targeting chimera (PROTAC) is a TDP strategy based on the ubiquitin-proteasome system (UPS). PROTAC is a bifunctional molecule that structurally consists of three parts: a ligand for the target protein (POI), a ligand for binding and recruiting E3 ubiquitin ligase, and a linker connecting the two ligands. Mechanistically, PROTAC molecules can induce the target protein and the ligase to approach each other, forming a ternary complex of E3 ligase-PROTAC-target protein. Subsequently, through the UPS system, the target protein is ubiquitin-tagged and finally targeted for degradation by the proteasome. PROTAC drug molecules have the advantages of the above-mentioned TPD and can work using catalytic amounts. They can not only inhibit protein activity, but also degrade the entire protein, thereby destroying the enzymatic and non-enzymatic functions (such as scaffold function) or transcriptional functions of the protein. PROTAC technology has greatly broadened the possibilities of drug development in target selection and has shown great promise in the treatment of diseases such as tumors, autoimmune diseases, neurodegenerative diseases, and viral infections.
[0005] Effective and selective PROTAC drug molecules can act as IRAK degraders to block IRAK-dependent pro-inflammatory signaling, thereby providing therapeutic benefits for inflammatory diseases and tumors characterized by dysregulated IRAK kinase activity. Therefore, in this field, the development of such molecules is a research focus. Summary of the invention
[0006] In view of the shortcomings of the prior art, the purpose of the present invention is to provide a protein degradation targeting chimeric molecule and its application. The protein degradation targeting chimeric molecule of the present invention can significantly degrade IRAK kinase, and it shows efficient and highly selective IRAK4 and / or IRAK1 degradation, and can be used to treat or prevent diseases related to IRAK4 and / or IRAK1 activity.
[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0008] In a first aspect, the present invention provides a protein degradation targeting chimeric molecule or its mesomorph, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the protein degradation targeting chimeric molecule has a structure shown in formula (I):
[0009]
[0010] Among them, PTM is the IRAK protein targeting moiety, which is a small molecule that has an inhibitory effect on the kinase activity of IRAK, and is composed of the small molecule part containing amide and three heteroaromatic rings on the left side of formula (I), ring A and ring B.
[0011] R f is selected from halogen or C1-C3 alkyl, wherein the C1-C3 alkyl is unsubstituted or substituted by a deuterium atom and / or a halogen atom; preferably, R f Selected from -CF2CF3, -CF3, -CH3, -CD3, -CF2H, -CF2D, -CFH2 or -CFD2;
[0012] Ring A and Ring B are each independently absent or a 4-10 membered cycloalkyl or heterocyclic group, and contain 0-2 heteroatoms independently selected from N, O and S, and the cycloalkyl or heterocyclic group is substituted or unsubstituted, and when substituted, the substituents are independently selected from one or at least two of a deuterium atom, a halogen, an amino group, a hydroxyl group, a thiol group, a nitro group, a cyano group, a carbonyl group, a carboxyl group, an ester group, an alkenyl group, an alkynyl group, an alkyl group, an alkoxy group, a hydroxyalkyl group, an alkylthio group, an alkylamino group, a cycloalkyl group, a heterocyclic group, a cycloalkyloxy group, a cycloalkylthio group, a heterocycloalkyloxy group, a heterocycloalkylthio group, an aryl group or a heteroaryl group;
[0013] LBM is an E3 ubiquitin ligase binding moiety, selected from E3 ubiquitin ligase ligands such as CRBN (cereblon), VHL (von Hippel-Lindau), IAP (inhibitor of apoptosis) and MDM2 (murine double minute 2), including but not limited to the following structures:
[0014]
[0015]
[0016] The wavy lines represent the attachment sites of the groups;
[0017] L is a linker connecting PTM and LBM, selected from C1-C 20 Alkyl, or C1-C 20 0, 1, 2, 3, 4, 5 or 6 -CH2- on the alkyl group are optionally replaced by one or at least two of the following atoms or groups: -O-, -S-, -NR a -, carbonyl, alkenyl, alkynyl, -C(O)R a -、-O(O)CR a -、-C(O)OR a -、-C(O)NR a -、-NHC(O)R a -、-S(O)R a -、-S(O)2R a -、-S(O)NR a -、-S(O)2NR a -、-NHS(O)R a -、-NHS(O)2R a -、-P(O)R a -、-P(O)NR a -, aryl, heteroaryl, cycloalkyl, heterocyclic radical, wherein the carbonyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic radical is optionally substituted by one or at least two groups selected from deuterium atom, halogen, amino, hydroxyl, mercapto, nitro, cyano, carbonyl, carboxyl, ester group, alkenyl, alkynyl, alkyl, alkoxy, hydroxyalkyl, alkylthio, alkylamino, cycloalkyl, heterocyclic radical, cycloalkyloxy, cycloalkylthio, heterocycloalkyloxy, heterocycloalkylthio, aryl and heteroaryl; wherein R a R is independently selected from H, D, halogen, amino, hydroxyl, mercapto, nitro, cyano, carbonyl, carboxyl, ester, alkenyl, alkynyl, alkyl, alkoxy, cycloalkyl, heterocyclic radical, aryl, heteroaryl, wherein the alkenyl, alkynyl, alkyl, alkoxy, cycloalkyl, heterocyclic radical, aryl and heteroaryl are optionally substituted with one or at least two groups selected from deuterium atom, halogen, amino, hydroxyl, mercapto, nitro, cyano, carbonyl, carboxyl, ester, alkenyl, alkynyl, alkyl, alkoxy, cycloalkyl, heterocyclic radical, aryl and heteroaryl; or R a Together with the atoms to which they are attached, they form a cycloalkyl or heterocyclic group, which is optionally substituted by one or at least two groups selected from a deuterium atom, a halogen, an amino group, a hydroxyl group, a mercapto group, a nitro group, a cyano group, a carbonyl group, a carboxyl group, an ester group, an alkenyl group, an alkynyl group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group;
[0018] Preferably, L includes but is not limited to the following structures:
[0019]
[0020]
[0021] x, y and z are each independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and the wavy line represents the attachment site of the group.
[0022] Preferably, non-limiting examples of L include but are not limited to the following L15 and L16:
[0023]
[0024] Wherein, preferably, x and y are each independently 0, 1, 2, 3, 4 or 5, and the wavy line represents the connection site of the group.
[0025] In a preferred embodiment, the protein degradation targeting chimeric molecule is a compound represented by the general formula (II):
[0026]
[0027] Among them, R f , L and LBM are as defined in the general formula (I).
[0028] In another preferred embodiment, the protein degradation targeting chimeric molecule is a compound represented by the general formula (III):
[0029]
[0030] Among them, R f , L and LBM are as defined in the general formula (I).
[0031] Typical compounds of the present invention include, but are not limited to:
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039] In a second aspect, the present invention provides a pharmaceutical composition comprising the protein degradation targeting chimeric molecule as described in the first aspect or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.
[0040] In the third aspect, the present invention provides the use of the protein degradation targeting chimeric molecule as described in the first aspect or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt, or the pharmaceutical composition as described in the second aspect in the preparation of a medicament for treating and / or preventing diseases or disorders associated with IRAK kinase activity.
[0041] Preferably, the disease or disorder associated with IRAK kinase activity is selected from cancer, neurodegenerative disease, autoimmune disease, inflammatory disease, viral disease, cardiovascular disorder, kidney disease, liver disease, metabolic disorder, genetic disorder or proliferative disorder.
[0042] The cancer is selected from the group consisting of breast cancer, small cell lung cancer, non-small cell lung cancer, bronchoalveolar carcinoma, prostate cancer, bile duct cancer, bone cancer, bladder cancer, head and neck cancer, kidney cancer, liver cancer, gastrointestinal tissue cancer, esophageal cancer, ovarian cancer, pancreatic cancer, skin cancer, testicular cancer, thyroid cancer, uterine cancer, cervical and vaginal cancer, leukemia, multiple myeloma or lymphoma.
[0043] The autoimmune disease and inflammatory disease are selected from systemic lupus erythematosus, lupus nephritis, arthritis, psoriasis, Crohn's disease, atopic dermatitis, gout, protein-related periodic syndrome, chronic kidney disease or acute kidney injury, chronic obstructive pulmonary disease, asthma, bronchospasm or graft-versus-host disease.
[0044] Preferably, the IRAK kinase is one or a combination of at least two of IRAK1, IRAK2, IRAK3 and IRAK4.
[0045] Terminology
[0046] Unless stated otherwise, the terms used in the specification and claims have the following meanings.
[0047] In the present invention, when referring to a "compound" having a specific structural formula, it generally also encompasses pharmaceutically acceptable salts, stereoisomers, diastereomers, enantiomers, racemic mixtures and isotopic derivatives thereof.
[0048] It is well known to those skilled in the art that, in addition to salts of compounds, solvates and hydrates are alternative forms of existence of compounds, and they can all be converted into the compounds under certain conditions. Therefore, when a compound is mentioned in the present invention, its solvates and hydrates are generally also included.
[0049] The "pharmaceutically acceptable salt" of the present invention refers to a salt of the compound of the present invention, which is suitable for contact with human and mammalian tissues within the scope of reasonable medical judgment, without undue toxicity, irritation, allergic reaction, etc., and has due biological activity, which can be regarded as a reasonable benefit / risk ratio. The salt can be prepared in situ during the final separation and purification of the compound of the present invention, or prepared separately by reacting a free base or a free acid with a suitable reagent. For example, a free base can be reacted with a suitable acid. Examples of pharmaceutically acceptable acid addition salts are salts formed by amino (amine) groups with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid) or organic acids (e.g., acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid), or by using other methods in the prior art such as ion exchange. The pharmaceutically acceptable salts of the present invention can be prepared by conventional methods, for example, by dissolving the compound of the present invention in a water-miscible organic solvent (e.g., methanol, ethanol, acetone and acetonitrile), adding an excess of an organic acid or an aqueous inorganic acid solution thereto to precipitate the salt from the resulting mixture, removing the solvent and the remaining free acid therefrom, and then isolating the precipitated salt. Other pharmaceutically acceptable salts include sodium alginate, ascorbate, benzenesulfonate, adipate, camphorsulfonate, aspartate, benzoate, bisulfate, borate, butyrate, camphorate, citrate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, heptanoate, hexanoate, hydroiodide, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, bitter salt, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate and the like.
[0050] "Solvate" as used herein means a physical association of a compound of the invention with one or more solvent molecules (whether organic or inorganic). The physical association includes hydrogen bonding. In some cases, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid, the solvate will be able to be separated. The solvent molecules in the solvate may exist in a regular arrangement and / or a disordered arrangement. The solvate may contain stoichiometric or non-stoichiometric amounts of solvent molecules. "Solvate" encompasses solution phases and separable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Solvation methods are well known in the art.
[0051] The "stereoisomerism" described in the present invention is divided into conformational isomerism and configurational isomerism. Configurational isomerism can also be divided into cis-trans isomerism and optical isomerism (i.e. optical isomerism). Conformational isomerism refers to a stereoisomerism phenomenon in which the atoms or atomic groups of an organic molecule with a certain configuration have different arrangements in space due to the rotation or distortion of carbon and carbon single bonds. Common examples include the structures of alkane and cycloalkane compounds, such as the chair conformation and boat conformation that appear in the structure of cyclohexane. "Stereoisomer" refers to when the compounds of the present invention contain one or more asymmetric centers, and thus can be used as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and single diastereoisomers. The compounds of the present invention have asymmetric centers, and each asymmetric center will produce two optical isomers. The scope of the present invention includes all possible optical isomers and diastereomeric mixtures and pure or partially pure compounds.
[0052] Particularly, the compounds of the present invention can exist in tautomeric forms, which have different hydrogen attachment points through one or more double bond displacements. For example, a ketone and its enol form are keto-enol tautomers. Each tautomer and its mixture are included in the compounds of the present invention. Enantiomers, diastereomers, racemates, mesomorphs, cis-trans isomers, tautomers, geometric isomers, epimers and mixtures thereof of all compounds are included in the scope of the present invention.
[0053] The "isotope derivative" of the present invention refers to a molecule in which the compound of the present invention is isotopically labeled. The isotopes commonly used as isotope labels are: Hydrogen isotopes: 2 H and 3 H; Carbon isotope: 11 C, 13 C and 14 C; Chlorine isotope: 35 Cl and 37 Cl; Fluorine isotope: 18 F; Iodine isotope: 123 I and 125 I; Nitrogen isotopes: 13 N and15 N; oxygen isotope: 15 Oh, 17 O and 18 O; Sulfur isotopes: 35 S. These isotope-labeled compounds can be used to study the distribution of drug molecules in tissues. 2 H) substitution can enhance metabolic stability, prolong half-life, thereby achieving the purpose of reducing dosage and providing therapeutic advantages. Isotope-labeled compounds generally start from labeled starting materials and use known synthesis techniques to complete their synthesis like non-isotope-labeled compounds.
[0054] In the present invention, a given chemical formula or name shall encompass all stereo and optical isomers and racemates in which the above isomers exist. Unless otherwise indicated, all chiral (enantiomers and diastereomers) and racemic forms are within the scope of the present invention. Many geometric isomers of C=C double bonds, C=N double bonds, ring systems, etc. may also exist in the compounds, and all the above stable isomers are encompassed by the present invention. The present invention describes cis- and trans- (or E- and Z-) geometric isomers of the compounds of the present invention, and they can be separated into mixtures of isomers or separated isomeric forms.
[0055] The compounds of the present invention may be isolated in optically active or racemic forms. All methods for preparing the compounds of the present invention and intermediates prepared therein are considered part of the present invention. When enantiomers or diastereoisomers are prepared, they may be separated by conventional methods (e.g., by chromatography or fractional crystallization). It should be understood that all tautomeric forms that may exist are included in the present invention. The compounds of the present invention are commercially available as known compounds of the prior art.
[0056] The term "alkyl" refers to a saturated aliphatic hydrocarbon group including branched and straight chain groups having a specified number of carbon atoms. The alkyl group in the present invention is preferably C1-C 12 Alkyl, C1-C 10C1-C8 alkyl, C1-C6 alkyl, more preferably C1-C4 alkyl, especially C1-C3 alkyl. For example, "C1-C6 alkyl" means an alkyl with 1 to 6 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, tert-butyl) and pentyl (e.g., n-pentyl, isopentyl, neopentyl). Alkyl can be substituted or unsubstituted, and when substituted, the substituent can be substituted at any usable point of attachment, and the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carbonyl, carboxyl or carboxylate. For C1-C8 alkyl in the present invention, alkyl, C1-C8 alkyl, C1-C8 alkyl, more preferably C1-C6 alkyl, especially C1-C4 alkyl, especially C1-C3 alkyl. 12 In the case of an alkyl group, 1 to 4 -CH2- units are optionally replaced by O atoms, S atoms or -NH-.
[0057] The term "alkoxy" refers to -O-(alkyl) or -O-(unsubstituted cycloalkyl). For example, "C1-C6 alkoxy" refers to C1, C2, C3, C4, C5, C6 alkoxy. Preferred alkoxy is C1-C 10 Alkoxy, C1-C8 alkoxy, more preferably C1-C6 alkoxy, particularly preferably C1-C4 alkoxy, especially C1-C3 alkoxy. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), tert-butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy. Alkoxy can be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate. Similarly, "alkylthio" means an alkyl group as defined above connected by a sulfur bridge with a specified number of carbon atoms; for example, methyl-S- and ethyl-S-. Similarly, preferred alkylthio is C1-C 10 Alkylthio, C1-C8 alkylthio, more preferably C1-C6 alkylthio, particularly preferably C1-C4 alkylthio, especially C1-C3 alkylthio.
[0058] The term "alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc. The alkenyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.
[0059] The term "alkynyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, such as ethynyl, propynyl, butynyl, etc. Alkynyl may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.
[0060] The term "halo" or "halogen" includes fluorine, chlorine, bromine and iodine. In the present invention, one or more halogens can be independently selected from fluorine, chlorine, bromine and iodine.
[0061] The term "haloalkyl" refers to branched and straight chain saturated aliphatic hydrocarbon groups having a specified number of carbon atoms and substituted with one or more halogens. Examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl.
[0062] The term "carbonyl" or "oxo" refers to an organic functional group consisting of carbon and oxygen atoms connected by a double bond (C=O or C(O)).
[0063] The term "benzyl" refers to -CH2-phenyl or "Bn".
[0064] The term "hydroxy" refers to an -OH group.
[0065] The term "amino" refers to -NH2.
[0066] The term "cyano" refers to -CN.
[0067] The term "nitro" refers to -NO2.
[0068] The term "carboxy" refers to -C(O)OH.
[0069] The term "thiol" refers to -SH.
[0070] The term "ester" or "carboxylate" refers to a -C(O)O-(alkyl) or -C(O)O-(cycloalkyl) group, wherein alkyl and cycloalkyl are as defined above.
[0071] The term "acyl" refers to a compound containing a -C(O)R group, wherein R is alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
[0072] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring contains 3 to 20 carbon atoms, and the cycloalkyl of the present invention is preferably C3-C8 cycloalkyl. Monocyclic cycloalkyl includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl and cyclooctyl, and polycyclic cycloalkyl includes but is not limited to cycloalkyl of spiro ring, condensed ring and bridge ring, such as norbornyl.
[0073] The term "spirocycloalkyl" refers to a polycyclic group of 5 to 20 members, containing two or more cyclic structures, and in which the monocyclic rings share one atom (called a spiro atom) with each other, containing one or more double bonds in the ring, but no ring has a completely conjugated π-electron aromatic system. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of spiro atoms shared between the rings, the spirocycloalkyl is divided into a single spiro, a double spiro or a multi-spirocycloalkyl, preferably a single spiro and a double spirocycloalkyl, preferably 4 / 5 members, 4 / 6 members, 5 / 5 members or 5 / 6 members. Non-limiting examples of "spirocycloalkyl" include, but are not limited to:
[0074]
[0075] The term "condensed cycloalkyl" refers to a 5 to 20-membered polycyclic group containing two or more cyclic structures sharing a pair of atoms adjacent to each other, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron aromatic system, preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyl, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl. Non-limiting examples of "condensed cycloalkyl" include, but are not limited to:
[0076]
[0077] The term "bridged cycloalkyl" refers to a 5 to 20-membered polycyclic group containing two or more cyclic structures, sharing two atoms that are not directly connected to each other, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron aromatic system, preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of "bridged cycloalkyl" include, but are not limited to:
[0078]
[0079] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocyclyl ring, wherein the ring connected to the parent structure is a cycloalkyl, non-limiting examples of which include but are not limited to:
[0080]
[0081] The cycloalkyl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carbonyl, carboxyl or carboxylate.
[0082] The term "heterocyclyl" or "heterocycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which are heteroatoms selected from N, O and S (N and S heteroatoms may be optionally oxidized), but excluding the ring part of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; most preferably, it contains 3 to 8 ring atoms, of which 1 to 3 are heteroatoms; most preferably, it contains 5 to 7 ring atoms, of which 1 to 2 or 1 to 3 are heteroatoms. Examples of monocyclic heterocyclyls include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl and tetrahydropyranyl, and polycyclic heterocyclyls include, but are not limited to, spirocyclic, fused and bridged heterocyclyls.
[0083] The term "spiro heterocyclic group" refers to a polycyclic group of 5 to 20 members, containing two or more cyclic structures, and sharing one atom between monocyclic rings, containing one or more double bonds in the ring, but no ring has a completely conjugated π electron aromatic system, and one or more ring atoms are selected from heteroatoms of N, O and S (N and S heteroatoms may be optionally oxidized), and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of shared spiral atoms between rings, the spiro heterocyclic group is divided into a single spiral heterocyclic group, a double spiral heterocyclic group or a multi-spiro heterocyclic group, preferably a single spiral heterocyclic group and a double spiral heterocyclic group. More preferably, it is a 4-member / 4-member, 4-member / 5-member, 4-member / 6-member, 5-member / 5-member or 5-member / 6-member single spiral heterocyclic group. Non-limiting examples of "spiro heterocyclic group" include, but are not limited to:
[0084]
[0085] The term "fused heterocyclic group" refers to a 5 to 20-membered polycyclic group containing two or more cyclic structures sharing a pair of adjacent atoms, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron aromatic system, wherein one or more ring atoms are selected from N, O and S heteroatoms (N and S heteroatoms may be optionally oxidized), and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group. Non-limiting examples of "fused heterocyclic groups" include, but are not limited to:
[0086]
[0087] The term "bridged heterocyclic group" refers to a 5 to 20-membered polycyclic group containing two or more cyclic structures, sharing two atoms that are not directly connected to each other, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π-electron aromatic system, wherein one or more ring atoms are selected from N, O and S heteroatoms (N and S heteroatoms may be optionally oxidized), and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of "bridged heterocyclic groups" include, but are not limited to:
[0088]
[0089] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclyl, non-limiting examples of which include but are not limited to:
[0090]
[0091] The heterocyclyl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carbonyl, carboxyl or carboxylate.
[0092] The term "aryl" refers to a monocyclic, bicyclic or tricyclic ring system having a conjugated π electron system with a total of 6 to 14 ring atoms, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring atoms. In certain embodiments of the present invention, "aryl" refers to an aromatic ring system, which includes but is not limited to phenyl, naphthyl, biphenyl, indanyl, 1-naphthyl, 2-naphthyl and tetrahydronaphthyl. The aryl of the present invention is preferably C6-C 10 Aryl. Aryl may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0093] The term "heteroaryl" refers to a stable 3-, 4-, 5-, 6-, or 7-membered aromatic monocyclic or 7-, 8-, 9-, or 10-membered aromatic bicyclic or aromatic polycyclic heterocyclic ring, which is completely unsaturated or partially unsaturated, and which contains carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S (N and S heteroatoms may be optionally oxidized). The nitrogen atom is substituted or unsubstituted (i.e., N or NR, wherein R is H or, if defined, another substituent). The heterocycle may be connected to its side group at any heteroatom or carbon atom that results in a stable structure. If the resulting compound is stable, the heterocyclic group of the present invention may be substituted on a carbon or nitrogen atom. The nitrogen in the heterocycle may be optionally quaternized. Preferably, when the total number of S and O atoms in the heterocycle exceeds 1, these heteroatoms are not adjacent to each other. Preferably, the total number of S and O atoms in the heterocycle is not greater than 1. When the term "heterocycle" is used, it is intended to include heteroaryl. Examples of heteroaryl include, but are not limited to, acridinyl, imidazolyl, furanyl, thienyl, oxazolyl, thiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, indolyl, indolizinyl, indazolyl, pyrimidinyl, phenazinyl, piperazinyl, piperidinyl, purinyl, pyranyl, pyrazinyl, pyrrolyl and quinolinyl. The term "heteroaryl" may also include biaryl structures formed by the above-defined "aryl", "heterocyclyl" or "cycloalkyl" and monocyclic "heteroaryl", such as, but not limited to, "-phenylbipyridyl-", "-phenylbipyrimidyl-", "-pyridylbinaphthyl-", "-pyrimidylbinaphthyl-" and "-pyridylbipyrimidyl-", wherein the present invention also includes spirocyclic, condensed ring and bridged ring compounds containing, for example, the above-mentioned heterocyclic rings.
[0094] The term "optional" or "optionally" as used herein means that the event or circumstance described subsequently may but need not occur, and the description includes occasions where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes situations where the heterocyclic group is substituted with an alkyl group and situations where the heterocyclic group is not substituted with an alkyl group.
[0095] "Substitution" or "substituted" as used herein refers to one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, being replaced by a corresponding number of substituents independently of one another, provided that normal valence is maintained and the substitution results in a stable compound. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (such as olefin) bond.
[0096] "Pharmaceutical composition" means a mixture containing one or more compounds of the present invention or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredients, and thus exert biological activity.
[0097] Compared with the prior art, the present invention has the following beneficial effects:
[0098] The protein degradation targeting chimeric molecule of the present invention can significantly degrade IRAK kinase, and shows efficient and highly selective IRAK4 and / or IRAK1 degradation effects, and can be used to treat or prevent diseases associated with IRAK4 and / or IRAK1 activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0099] Figure 1 This is a graph showing the results of the compound's degradation of IRAK4 in THP-1 cells;
[0100] Figure 2 This is a graph showing the test results of the effects of compounds on downstream signaling molecules in the TLR signaling pathway in THP-1 cells. DETAILED DESCRIPTION
[0101] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0102] The embodiments of the present invention, including the description provided in the embodiments, are intended to illustrate embodiments of the present invention and are not intended to limit the scope of any claims. According to the present invention, it will be appreciated by those skilled in the art that many changes may be made to the disclosed specific embodiments without departing from the spirit and scope of the present invention and still achieving the same or similar results.
[0103] Unless otherwise stated, all materials / reagents were obtained from commercial suppliers and used without further purification. The structures of the compounds of the following examples were characterized and confirmed by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS).
[0104] 1 H NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer at room temperature, with the solvents being deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD) or deuterated water (D2O). Chemical shift values (δ) are in ppm, with tetramethylsilane (TMS) or residual solvent peak as internal standard, and coupling constants (J) are in Hertz (Hz). 1The abbreviations for the multiplicity of peaks in H NMR spectra are as follows: s (singlet), d (doublet), t (triplet), q (quartet), qn (quintet), m (multiplet), br (broad).
[0105] The instrument used for liquid chromatography-mass spectrometry (LC-MS) is Shimadzu LCMS-2020, and the instrument used for preparative high performance liquid chromatography (Prep-HPLC) is Bonna-Agela FLEXA FL-H100G. The thin layer chromatography silica gel plate model used for thin layer chromatography (TLC) is Yantai Huanghai HSGF254 thin layer chromatography silica gel plate. The specification used for reaction monitoring is 2.5×8cm, and its coating thickness is 0.2±0.03mm. The specification used for separation and purification is 20×20cm, and its coating thickness is 0.4-0.5mm. The silica gel model used for silica gel column chromatography is 100-200 mesh or 200-300 mesh silica gel from Qingdao Bay Fine Chemicals.
[0106] Intermediate 1: Synthesis of 6-(1H-pyrazol-3-yl)picolinic acid (Int-1)
[0107]
[0108] Synthesis route:
[0109]
[0110] 1-(Tetrahydropyranyl)-1H-pyrazole-5-boronic acid pinacol ester Int-1a (15.3 g, 55.0 mmol), 6-bromo-2-pyridinecarboxylic acid Int-1b (10.1 g, 50.0 mmol), tetrakis(triphenylphosphine)palladium (1.0 g, 0.86 mmol), sodium carbonate (10.6 g, 100.0 mmol), 1,4-dioxane (300 mL) and water (60 mL) were added to a round-bottom flask in sequence at room temperature. The air in the flask was quickly replaced with nitrogen three times, and the reaction solution was heated to 80°C and stirred for 16 hours. TLC and LC-MS showed that the reaction was complete. After the reaction solution was cooled to room temperature, water (300 mL) was added to quench it, and it was extracted with ethyl acetate (300 mL). The aqueous phase was acidified with dilute hydrochloric acid (4N) to pH = 3, and a large amount of solid precipitated. The mixture was stirred at room temperature for half an hour, filtered, and the filter cake was washed with water. After drying, compound Int-1 (9.0 g, yield 95%) was obtained as a yellow solid.
[0111] MS(ES + ):m / z 190.0[M+H] + .
[0112] Intermediate 2: Synthesis of 3-(difluoromethyl)-4-nitro-1H-pyrazole (Int-2)
[0113]
[0114] Synthesis route:
[0115]
[0116] Step 1: Synthesis of 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3-carbaldehyde (Int-2c)
[0117] 1H-pyrazole-3-carboxaldehyde Int-2a (19.2 g, 200.0 mmol), 3,4-dihydro-2H-pyran Int-2b (17.7 g, 210.0 mmol), p-toluenesulfonic acid (2.4 g, 14.0 mmol) and tetrahydrofuran (400 mL) were added to a round-bottom flask at room temperature, and the reaction solution was kept at 70°C and refluxed and stirred for 2 hours. TLC and LC-MS showed that the reaction was complete. After the reaction solution was cooled to room temperature, it was concentrated under reduced pressure to remove the solvent, and then purified by silica gel column chromatography (petroleum ether containing 6% ethyl acetate as eluent) to obtain compound Int-2c (34.0 g, yield 94%).
[0118] MS(ES + ):m / z 181.1[M+H] + .
[0119] Step 2: Synthesis of 3-(difluoromethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (Int-2d)
[0120] Diethylaminosulfur trifluoride (DAST, 40.2 g, 250.0 mmol) was slowly added dropwise to a solution of compound Int-2c (18.0 g, 100.0 mmol) in dichloromethane (300 mL) at 0°C in an ice bath, and the reaction solution was stirred for 5 hours at 0°C in an ice bath. TLC and LC-MS showed that the reaction was complete, and the reaction mixture was poured into water (200 mL), and the pH was adjusted to neutral with a 5% aqueous sodium bicarbonate solution, and then extracted with dichloromethane (200 mL×3). The organic phases were combined, washed with saturated brine (600 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude product of compound Int-2d (20.0 g), which was directly used in the next step.
[0121] MS(ES + ):m / z 203.1[M+H] + .
[0122] Step 3: Synthesis of 3-(difluoromethyl)-1H-pyrazole (Int-2e)
[0123] Concentrated hydrochloric acid (30 mL) was slowly added dropwise to a solution of the crude product of compound Int-2d (20.0 g) in 1,4-dioxane (100 mL) at room temperature, and the reaction solution was stirred at 90°C for 2 hours. TLC and LC-MS showed that the reaction was complete, and the reaction mixture was poured into ice water (400 mL) and extracted with ethyl acetate (300 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a crude product of compound Int-2e (12.0 g), which was directly used in the next step.
[0124] MS(ES + ):m / z 119.0[M+H] + .
[0125] Step 4: Synthesis of 3-(difluoromethyl)-4-nitro-1H-pyrazole (Int-2)
[0126] Concentrated nitric acid (36 mL) was slowly added dropwise to a solution of the crude product of compound Int-2e (12.0 g) in concentrated sulfuric acid (120 mL) under an ice bath at 0°C, and then the reaction solution was heated to 120°C and stirred for 3 hours. TLC and LC-MS showed that the reaction was complete, and the reaction mixture was slowly poured into ice water (600 mL) and directly extracted with ethyl acetate (400 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (petroleum ether containing 9% ethyl acetate as eluent) to obtain compound Int-2 (11.0 g, three-step yield 67%) as a yellow solid.
[0127] MS(ES + ):m / z 164.0[M+H] + .
[0128] Intermediate 3: Synthesis of tert-butyl 4-(3-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)azetidin-1-yl)piperidine-1-carboxylate (Int-3)
[0129]
[0130] Synthesis route:
[0131]
[0132] Step 1: Synthesis of tert-butyl 3-(p-toluenesulfonyloxy)azetidine-1-carboxylate (Int-3b)
[0133] To a solution of N-Boc-3-hydroxyazetidine Int-3a (50.0 g, 288.7 mmol) in dichloromethane (500 mL) was added p-toluenesulfonyl chloride (54.9 g, 288.0 mmol) and pyridine (27.4 g, 347.0 mmol) under an ice bath at 0°C. The reaction solution was naturally warmed to room temperature and stirred for 36 hours. TLC and LC-MS showed that the reaction was complete. The reaction mixture was poured into water (500 mL), separated, and the aqueous phase was extracted with dichloromethane (500 mL×2). The organic phases were combined, washed with 5% aqueous sodium bicarbonate solution and saturated brine in sequence, dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (petroleum ether containing 25% ethyl acetate as eluent) to obtain compound Int-3b (86.5 g, yield 92%).
[0134] MS(ES + ):m / z 328.1[M+H] + .
[0135] Step 2: Synthesis of tert-butyl 3-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)azetidine-1-carboxylate (Int-3c)
[0136] Compound Int-2 (16.3 g, 100.0 mmol), Int-3b (36.0 g, 110.0 mmol), potassium carbonate (20.7 g, 150.0 mmol) and dimethyl sulfoxide (150 mL) were added to a round-bottom flask in sequence at room temperature, and the reaction solution was heated to 100 ° C and stirred for 16 hours. TLC and LC-MS showed that the reaction was complete. After the reaction solution was cooled to room temperature, water (400 mL) was added to quench it and extracted with ethyl acetate (300 mL×3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (petroleum ether containing 25% ethyl acetate as eluent) to obtain compound Int-3c (19.5 g, yield 92%).
[0137] MS(ES + ):m / z 319.1[M+H] + .
[0138] Step 3: Synthesis of tert-butyl 4-(3-(3-(difluoromethyl)-4-nitro-1H-pyrazol-1-yl)azetidin-1-yl)piperidine-1-carboxylate (Int-3d)
[0139] Trifluoroacetic acid (30 mL) was slowly added dropwise to a solution of compound Int-3c (15.9 g, 50.0 mmol) in dichloromethane (100 mL) at room temperature, and the reaction solution was stirred at room temperature for 1 hour. TLC and LC-MS showed that the reaction was complete, and the reaction solution was concentrated under reduced pressure to remove the dichloromethane solvent and trifluoroacetic acid to obtain a light yellow solid. The concentrated crude product was dissolved in methanol (200 mL), and the solution was adjusted to weak alkalinity (pH = 8) with triethylamine, and N-Boc-4-piperidone (10.0 g, 50.0 mmol) and palladium carbon (10% wet powder, 50 wt% water, 4.2 g) were added to the solution, and a hydrogen balloon was added. After the air in the bottle was quickly replaced with hydrogen three times, the reaction solution was kept stirring at room temperature for 16 hours under the protection of a hydrogen atmosphere. TLC and LC-MS showed that the reaction was complete. The palladium carbon solid was removed by filtration, and the filter cake was washed with methanol. The filtrate was concentrated under reduced pressure and then purified by silica gel column chromatography (petroleum ether containing 25% ethyl acetate as eluent) to give compound Int-3d (18.4 g, yield 92%).
[0140] MS(ES + ):m / z 402.2[M+H] + .
[0141] Step 4: Synthesis of tert-butyl 4-(3-(4-amino-3-(difluoromethyl)-1H-pyrazol-1-yl)azetidin-1-yl)piperidine-1-carboxylate (Int-3)
[0142] Palladium carbon (10% wet powder, 50wt% water, 2.1g) was added to a solution of compound Int-3d (10.0g, 24.9mmol) in methanol (50mL) at room temperature, and a hydrogen balloon was added. After the air in the bottle was quickly replaced with hydrogen three times, the reaction solution was kept stirring at room temperature for 4 hours under the protection of hydrogen atmosphere. TLC and LC-MS showed that the reaction was complete, and the palladium carbon solid was removed by suction filtration. The filter cake was washed with methanol, and the filtrate was concentrated under reduced pressure, and then purified by silica gel column chromatography (dichloromethane containing 9% methanol as eluent) to obtain compound Int-3 (7.9g, yield 85%) as a white solid.
[0143] MS(ES + ):m / z 372.2[M+H] + .
[0144] Intermediate 4: Synthesis of N-(3-(difluoromethyl)-1-(1-(piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (Int-4)
[0145]
[0146] Synthesis route:
[0147]
[0148] Step 1: Synthesis of tert-butyl 4-(3-(4-(6-(1H-pyrazol-3-yl)picolinamido)-3-(difluoromethyl)-1H-pyrazol-1-yl)azetidin-1-yl)piperidine-1-carboxylate (Int-4a)
[0149] 4-Dimethylaminopyridine (DMAP, 4.9 g, 40.0 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 4.2 g, 22.0 mmol) were added to a solution of compound Int-1 (3.8 g, 20.0 mmol) and Int-3 (7.4 g, 20.0 mmol) in dichloromethane (100 mL) at room temperature, and the reaction solution was stirred at room temperature for 12 hours. TLC and LC-MS showed that the reaction was complete, and the reaction mixture was poured into water (100 mL) and extracted with dichloromethane (100 mL×3). The organic phases were combined, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (dichloromethane containing 9% methanol as eluent) to obtain compound Int-4a (9.4 g, yield 87%) as a light yellow solid.
[0150] MS(ES + ):m / z 543.3[M+H] + .
[0151] Step 2: Synthesis of N-(3-(difluoromethyl)-1-(1-(piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (Int-4)
[0152] To a solution of compound Int-4a (2.7 g, 5.0 mmol) in dichloromethane (20 mL) was added a solution of hydrogen chloride in 1,4-dioxane (4 N, 25 mL) at room temperature, and the reaction solution was stirred at room temperature for 2 hours. TLC and LC-MS showed that the reaction was complete, and the reaction solution was concentrated under reduced pressure to remove the solvent and other volatiles to obtain a yellow solid crude product. The concentrated crude product was then dissolved in methanol (50 mL), potassium carbonate (13.8 g, 100.0 mmol) was added to the solution, stirred at room temperature for 1 hour, filtered to remove the solid, and the filtrate was concentrated under reduced pressure, and then purified by silica gel column chromatography (dichloromethane containing 9% methanol as the eluent) to obtain compound Int-4 (2.1 g, yield 95%) as a white solid.
[0153] MS(ES +):m / z 443.2[M+H] + .
[0154] Intermediate 5: Synthesis of 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Int-5)
[0155]
[0156] Synthesis route:
[0157]
[0158] To a suspension of 7-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one Int-5a (3.0 g, 13.2 mmol) in tetrahydrofuran (15 mL) was slowly added a solution of lithium bis(trimethylsilyl)amide (LiHMDS) in tetrahydrofuran (1.0 M, 33 mL) at room temperature for 15 minutes, and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was then slowly added to a solution of 3-bromopiperidine-2,6-dione Int-5b (5.0 g, 26.4 mmol) in tetrahydrofuran (30 mL) at room temperature for 10 minutes, and the resulting reaction mixture was heated to 60°C and stirred for 4 hours. TLC and LC-MS showed that the reaction was complete. The reaction mixture was poured into ice water (100 mL) and acidified to pH = 2 with dilute hydrochloric acid (2N). A large amount of solid precipitated, which was filtered and the filter cake washed with water to give compound Int-5 (2.85 g, yield 64%) as a gray solid.
[0159] MS(ES + ):m / z 338.0[M+H] + .
[0160] Intermediate 6: Synthesis of N-(1-(azetidin-3-yl)-3-(difluoromethyl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (Int-6)
[0161]
[0162] Synthesis route:
[0163]
[0164] Steps 1, 2 and 3 are the same as the synthetic routes and methods of intermediate 3 step 4, intermediate 4 step 1 and intermediate 4 step 2, respectively, except that compound Int-3d is replaced by an equivalent amount of compound Int-3c to obtain intermediate 6, i.e., compound Int-6, as a white solid.
[0165] MS(ES + ):m / z 360.1[M+H] + .
[0166] Example 1: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-((S)-14-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-15,15-dimethyl-12-oxo-3,6,9-trioxa-13-azepanhexadecyl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (1)
[0167]
[0168] Synthesis route:
[0169]
[0170] Step 1: Synthesis of tert-butyl 3-(2-(2-(2-(4-(3-(4-(6-(1H-pyrazol-3-yl)picolinamido)-3-(difluoromethyl)-1H-pyrazol-1-yl)azetidin-1-yl)piperidin-1-yl)ethoxy)ethoxy)ethoxy)propanoate (1b)
[0171] A mixture of compound Int-4 (619 mg, 1.40 mmol), potassium carbonate (387 mg, 2.80 mmol) and tert-butyl 3-(2-(2-(2-(p-toluenesulfonyloxy)ethoxy)ethoxy)ethoxy)propanoate 1a (636 mg, 1.47 mmol) was dissolved in N,N-dimethylformamide (5.0 mL) at room temperature, and the reaction solution was heated to 80°C and stirred for 5 hours. TLC and LC-MS showed that the reaction was complete. After the reaction solution was cooled to room temperature, the reaction mixture was poured into water (10 mL) and extracted with ethyl acetate (10 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (dichloromethane containing 10% methanol as eluent) to obtain compound 1b (826 mg, yield 84%) as a light yellow solid.
[0172] MS(ES + ):m / z 703.3[M+H] + .
[0173] Step 2: Synthesis of 3-(2-(2-(2-(4-(3-(4-(6-(1H-pyrazol-3-yl)picolinamido)-3-(difluoromethyl)-1H-pyrazol-1-yl)azetidin-1-yl)piperidin-1-yl)ethoxy)ethoxy)ethoxy)propanoic acid (1c)
[0174] Trifluoroacetic acid (0.4 mL) was added to a solution of compound 1b (200 mg, 0.28 mmol) in dichloromethane (3 mL) at room temperature, and the reaction solution was stirred at room temperature for 2 hours. TLC and LC-MS showed that the reaction was complete, and the solution was adjusted to weak alkalinity (pH = 8) with triethylamine. The reaction solution was concentrated under reduced pressure and purified by silica gel column chromatography (dichloromethane containing 10% methanol as eluent) to obtain compound 1c (163 mg, yield 90%) as a hygroscopic white solid.
[0175] MS(ES + ):m / z 647.3[M+H] + .
[0176] Step 3: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-((S)-14-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-15,15-dimethyl-12-oxo-3,6,9-trioxa-13-azepanadecanyl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (1)
[0177] Compound 1c (71 mg, 0.11 mmol), (2S,4R)-1-((S)-2-amino-3,3-dimethylbutyryl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride 1d (56 mg, 0.12 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 42 mg, 0.22 mmol), 1-hydroxybenzotriazole (HOBt, 30 mg, 0.22 mmol) and N,N-diisopropylethylamine (DIPEA, 84 mg, 0.65 mmol) were dissolved in dichloromethane (5 mL) at room temperature, and the reaction solution was stirred at room temperature for 15 h. TLC and LC-MS showed that the reaction was complete. The reaction solution was concentrated under reduced pressure and then separated and purified by Prep-HPLC (water containing 20-80% acetonitrile as the mobile phase) to obtain compound 1 (40 mg, yield 34%) as a white solid.
[0178] MS(ES + ):m / z 1059.5[M+H] + .
[0179] 1 H NMR (400MHz, CDCl3): δ10.48(s,1H),8.66(s,1H),8.43(s,1H),8.11(d,J=7.6Hz,1H),8.08(d,J=7.9Hz,1H),7.91(t,J=7.8Hz,1H),7.67(d,J= 1.8Hz,1H),7.60(t,J=5.7Hz,1H),7.32(s,4H),6.98(d,J=1.8Hz,1H),6.89(t,J=54.7Hz,1H),4.94(qn,J=6.9Hz,1H),4.73(t,J=8.0Hz,1H),4. 57–4.50(m,3H),4.33(dd,J=15.0,5.3Hz,1H),4.09(d,J=11.2Hz,1H),3.78(t,J=7.3Hz,2H),3.71(t,J=5.5Hz,2H),3.64–3.55(m,11H),3.45(t ,J=7.1Hz,2H),2.91–2.84(m,2H),2.58–2.55(m,2H),2.53–2.42(m,6H) ,2.26–2.00(m,5H),1.72–1.67(m,2H),1.44–1.36(m,2H),0.95(s,9H).
[0180] Example 2: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (2)
[0181]
[0182] Synthesis route:
[0183]
[0184] Step 1: Synthesis of 3-(3-methyl-2-methyl-4-(3-(tetrahydro-2H-pyran-2-yl)oxy)prop-1-yn-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (2b)
[0185] At room temperature, compound lnt-5 (676 mg, 2.0 mmol), bis(triphenylphosphine)palladium(II) dichloride (70 mg, 0.1 mmol), cuprous iodide (19 mg, 0.1 mmol), triethylamine (607 mg, 6.0 mmol), 2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran 2a (420 mg, 3.0 mmol) and N,N-dimethylformamide (10 mL) were added to a round-bottom flask in sequence, and the air in the tube was quickly replaced with nitrogen three times, and the reaction solution was kept at 80 ° C and stirred for 15 hours. TLC and LC-MS showed that the reaction was complete. After the reaction solution was cooled to room temperature, water (20 mL) was added to quench it and extracted with ethyl acetate (15 mL×3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (eluent: dichloromethane containing 5% methanol) to give compound 2b (690 mg, yield 87%) as a light yellow oil.
[0186] MS(ES + ):m / z 398.1[M+H] + .
[0187] Step 2: Synthesis of 3-(4-(3-hydroxyprop-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (2c)
[0188] Acetic acid (5 mL) and water (3 mL) were added to a solution of compound 2b (300 mg, 0.75 mmol) in tetrahydrofuran (5 mL) at room temperature, and the reaction solution was stirred at 50 ° C for 3 hours. TLC and LC-MS showed that the reaction was complete, and the pH was adjusted to neutral with saturated sodium bicarbonate aqueous solution, and then extracted with dichloromethane (15 mL × 3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (dichloromethane containing 5% methanol as eluent) to obtain compound 2c (184 mg, yield 78%) as a light yellow solid.
[0189] MS(ES + ):m / z 314.1[M+H] + .
[0190] Step 3: Synthesis of 3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)propynal (2d)
[0191] At room temperature, Dess-Martin Periodinane (254 mg, 0.60 mmol) was added to a solution of compound 2c (170 mg, 0.54 mmol) in dichloromethane (5 mL) and N,N-diisopropylethylamine (1 mL), and the reaction solution was stirred at 40 ° C for 2 hours. TLC and LC-MS showed that the reaction was complete, and water (10 mL) was added to quench, and the pH was adjusted to neutral with saturated sodium bicarbonate aqueous solution, and then extracted with dichloromethane (10 mL × 3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (dichloromethane containing 5% methanol as eluent) to obtain compound 2d (151 mg, yield 90%) as a light yellow solid.
[0192] MS(ES + ):m / z 312.1[M+H] + .
[0193] Step 4: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (2)
[0194] Compound 2d (124 mg, 0.40 mmol), compound Int-4 (177 mg, 0.40 mmol), tetrahydrofuran (4 mL) and methanol (6 mL) were added to a round-bottom flask at room temperature, and the reaction solution was stirred at 50 ° C for 1 hour, and then sodium cyanoborohydride (76 mg, 1.21 mmol) and acetic acid (0.5 mL) were added to the reaction solution, and the reaction solution was stirred at 50 ° C for 2 hours. TLC and LC-MS showed that the reaction was complete, and water (10 mL) was added to quench, and the pH was adjusted to neutral with saturated sodium bicarbonate aqueous solution, and then extracted with dichloromethane (10 mL × 3). After the organic phases were combined and concentrated under reduced pressure, they were separated and purified by Prep-HPLC (water containing 30–80% acetonitrile as the mobile phase) to obtain compound 2 (21 mg, yield 7%) as a white solid.
[0195] MS(ES + ):m / z 738.3[M+H] + .
[0196] 1H NMR (400MHz, DMSO-d6): δ13.86(minor),13.24(major)(s,1H),11.13(major),11.06(minor)(s,1H),10.59( minor),10.44(major)(s,1H),8.51(major),8.31(minor)(s,1H),8.24–8.14(m,1H),8.10(t,J=7.6Hz,1H), 8.02 (d, J = 7.9 Hz, 1H), 7.92(major), 7.66 (minor) (s, 1H), 7.45 – 6.94 (m, 5H), 5.39 (major), 5.31(minor)(dd,J=12.4,5.0Hz,1H),5.10(qn,J=7.0Hz,1H),3.78(t,J=6.9Hz,2H),3.66(major),3.59(minor)(s,3H),3.6 1(s,2H),2.90–2.84(m,2H),2.75–2.61(m,2H),2.35–2.27(m,3H),2.07–1.94(m,2H),1.78–1.71(m,2H),1.47–1.22(m,4H).
[0197] Example 3: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)but-3-yn-1-yl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (3)
[0198]
[0199] Synthesis route:
[0200]
[0201] Step 1: Synthesis of 3-(4-(4-hydroxybut-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (3b)
[0202] The synthetic route and method are the same as those of step 1 of Example 2, except that 2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran 2a is replaced by an equivalent amount of 3-butyn-1-ol 3a to obtain compound 3b.
[0203] MS(ES+ ):m / z 328.1[M+H] + .
[0204] Step 2: Synthesis of 3-(4-(4-bromobut-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (3c)
[0205] Carbon tetrabromide (120 mg, 0.36 mmol) was added to a solution of compound 3b (60 mg, 0.18 mmol) in dichloromethane (5 mL) at room temperature. After the air in the bottle was quickly replaced with nitrogen three times, the reaction solution was stirred at room temperature for 1 hour. Then the reaction solution was placed in an ice bath at 0°C, and a solution of triphenylphosphine (96 mg, 0.36 mmol) in dichloromethane (2 mL) was slowly added dropwise. The reaction solution was stirred for half an hour in an ice bath, and then heated to 50°C and stirred for 3 hours. TLC and LC-MS showed that the reaction was complete, and water (10 mL) was added to quench, and then extracted with dichloromethane (10 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (dichloromethane containing 5% methanol as eluent) to obtain compound 3c (23 mg, yield 33%) as a light yellow solid.
[0206] MS(ES + ):m / z 390.0[M+H] + .
[0207] Step 3: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)but-3-yn-1-yl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (3) To a solution of compound 3c (20 mg, 0.05 mmol) and compound Int-4 (23 mg, 0.05 mmol) in N,N-dimethylformamide (1 mL) was added N,N-diisopropylethylamine (DIPEA, 40 mg, 0.31 mmol) at room temperature, and the reaction solution was stirred at 70°C for 15 hours. TLC and LC-MS showed that the reaction was complete. After the reaction solution was cooled to room temperature, water (5 mL) was added to quench it, and then extracted with dichloromethane (5 mL × 3). The organic phases were combined and concentrated under reduced pressure, and then separated and purified by Prep-HPLC (water containing 30-80% acetonitrile as the mobile phase) to obtain compound 3 (5 mg, yield 13%) as a white solid.
[0208] MS(ES + ):m / z 752.4[M+H]+ .
[0209] 1 H NMR (400MHz, DMSO-d6): δ13.85(minor),13.22(major)(s,1H),11.12(major),11.03(minor)(s,1H),10.59( minor),10.44(major)(s,1H),8.51(major),8.30(minor)(s,1H),8.24–8.17(m,1H),8.11(t,J=7.4Hz,1H), 8.02 (d, J = 8.1 Hz, 1H), 7.92(major), 7.65 (minor) (s, 1H), 7.45 – 6.95 (m, 5H), 5.38 (major), 5.32(minor)(dd,J=12.6,5.4Hz,1H),5.07(qn,J=6.5Hz,1H),3.70(t,J=7.3Hz,2H),3.67(s,3H),2.90–2. 80(m,3H),2.71–2.56(m,5H),2.36–2.27(m,1H),2.16–1.97(m,4H),1.71–1.65(m,2H),1.24–1.16(m,4H).
[0210] Example 4: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(5-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)pent-4-yn-1-yl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (4)
[0211]
[0212] Synthesis route:
[0213]
[0214] Steps 1, 2 and 3 are the same as the synthetic routes and methods of steps 1, 3 and 4 of Example 2, respectively, except that 2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran 2a is replaced by an equivalent amount of 4-pentyn-1-ol 4a to obtain compound 4 as a white solid.
[0215] MS(ES + ):m / z 766.4[M+H] + .
[0216] 1 H NMR (400MHz, DMSO-d6): δ13.88(minor),13.23(major)(s,1H),11.11(major),11.02(minor)(s,1H),10.61( minor),10.44(major)(s,1H),8.52(major),8.32(minor)(s,1H),8.23–8.15(m,1H),8.10(t,J=7.3Hz,1H), 8.02 (d, J = 8.3 Hz, 1H), 7.92(major), 7.65 (minor) (s, 1H), 7.43 – 6.90 (m, 5H), 5.39 (major), 5.32(minor)(dd,J=12.8,5.5Hz,1H),5.09(qn,J=6.8Hz,1H),3.73(t,J=7.0Hz,2H),3.65(major),3.58(minor)(s,3H),2.94– 2.84(m,2H),2.77–2.63(m,4H),2.61–2.53(m,4H),2.34–2.32(m,1H),2.05–1.95(m,2H),1.91–1.74(m,4H),1.46–1.23(m,4H).
[0217] Example 5: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(6-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)hex-5-yn-1-yl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (5)
[0218]
[0219] Synthesis route:
[0220]
[0221] Steps 1, 2 and 3 are the same as the synthetic routes and methods of steps 1, 3 and 4 of Example 2, respectively, except that 2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran 2a is replaced by an equivalent amount of 5-hexyn-1-ol 5a to obtain compound 5 as a white solid.
[0222] MS(ES + ):m / z 780.4[M+H] + .
[0223] 1 H NMR (400MHz, DMSO-d6): δ10.49(s,1H),8.43(s,1H),8.17(d,J=7.6Hz,1H),8.11(t,J=7.7Hz, 1H),8.03(d,J=7.6Hz,1H),7.83(s,1H),7.46–6.91(m,5H),5.37(dd,J=12.8,5.8Hz,1H),5.06 (qn,J=6.8Hz,1H),3.68(t,J=6.8Hz,2H),3.64(s,3H),2.93–2.84(m,2H),2.78–2.59(m,4H),2 .33–2.27(m,3H),2.18–2.10(m,2H),2.04–1.90(m,4H),1.68–1.55(m,4H),1.23–1.14(m,4H).
[0224] Example 6: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(7-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)hept-6-yn-1-yl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (6)
[0225]
[0226] Synthesis route:
[0227]
[0228] Steps 1, 2 and 3 are the same as the synthetic routes and methods of steps 1, 3 and 4 of Example 2, respectively, except that 2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran 2a is replaced by an equivalent amount of 6-heptyn-1-ol 6a to obtain compound 6 as a white solid.
[0229] MS(ES + ):m / z 794.4[M+H] + .
[0230] 1H NMR (400MHz, DMSO-d6): δ13.87(minor),13.24(major)(s,1H),11.12(major),11.02(minor)(s,1H),10.60( minor),10.43(major)(s,1H),8.51(major),8.30(minor)(s,1H),8.24–8.16(m,1H),8.11(t,J=7.4Hz,1H), 8.03 (d, J = 8.0 Hz, 1H), 7.92(major), 7.67 (minor) (s, 1H), 7.41 – 6.91 (m, 5H), 5.38 (major), 5.32(minor)(dd,J=12.3,5.5Hz,1H),5.06(qn,J=6.9Hz,1H),3.68(t,J=7.1Hz,2H),3.64(major),3.57(minor)(s,3H),2.95–2.82(m,2 H),2.81–2.58(m,4H),2.34–2.25(m,3H),2.19–2.11(m,2H),2.05–1.95(m,2H),1.69–1.55(m,4H),1.51–1.37(m,4H),1.29–1.17(m,4H).
[0231] Example 7: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-3-oxopropoxy)ethyl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (7)
[0232]
[0233] Synthesis route:
[0234]
[0235] Step 1: Synthesis of 3-(2-bromoethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propanamide (7b)
[0236] A mixture of lenalidomide 7a (259 mg, 1.0 mmol), 3-(2-bromoethoxy)propionic acid 7b (295 mg, 1.5 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 383 mg, 2.0 mmol) was dissolved in N,N-dimethylformamide (5.0 mL) at room temperature, and the reaction solution was heated to 40°C and stirred for 15 hours. TLC and LC-MS showed that the reaction was complete, and the reaction mixture was poured into water (10 mL) and extracted with ethyl acetate (15 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (dichloromethane containing 5% methanol as eluent) to obtain compound 7c (153 mg, yield 35%) as a white solid.
[0237] MS(ES + ):m / z 438.0[M+H] + .
[0238] Step 2: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-3-oxopropoxy)ethyl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (7)
[0239] N,N-diisopropylethylamine (DIPEA, 26 mg, 0.20 mmol) was added to a solution of compound 7c (22 mg, 0.05 mmol) and compound Int-4 (23 mg, 0.05 mmol) in N,N-dimethylformamide (1 mL) at room temperature, and the reaction solution was stirred at 80 °C for 15 hours. TLC and LC-MS showed that the reaction was complete. After the reaction solution was cooled to room temperature, water (5 mL) was added to quench it, and then extracted with dichloromethane (5 mL×3). The organic phases were combined and concentrated under reduced pressure, and then separated and purified by Prep-HPLC (water containing 30–80% acetonitrile as the mobile phase) to obtain compound 7 (5 mg, yield 14%) as a white solid.
[0240] MS(ES + ):m / z 800.4[M+H] + .
[0241] 1H NMR (400MHz, DMSO-d6): δ11.04(s,1H),10.52(s,1H),9.86(s,1H),8.38(s,1H),8.19–8.14(m,2H),8.11(t,J=7 .7Hz,1H),8.03(d,J=7.8Hz,1H),7.97–7.81(m,2H),7.51–7.42(m,2H),7.24(t,J=54.1Hz,1H),7.02(d,J=1.8H z,1H),5.04(qn,J=6.7Hz,1H),4.78–4.66(m,1H),4.52–4.31(m,2H),3.71–3.62(m,4H),3.54–3.49(m,4H),2.7 9–2.73(m,2H),2.68–2.60(m,3H),2.48–2.44(m,2H),2.12–1.96(m,6H),1.61–1.52(m,2H),1.19–1.08(m,2H).
[0242] Example 8: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(3-(2-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)ethoxy)propanoyl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (8)
[0243]
[0244] Synthesis route:
[0245]
[0246] Step 1: Synthesis of tert-butyl 3-(2-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)ethoxy)propanoate (8b)
[0247] At room temperature, compound lnt-5 (338 mg, 1.0 mmol), bis(triphenylphosphine)palladium(II) dichloride (35 mg, 0.05 mmol), cuprous iodide (10 mg, 0.05 mmol), triethylamine (304 mg, 3.0 mmol), tert-butyl 3-(2-(prop-2-yn-1-yloxy)ethoxy)propionate 8a (342 mg, 1.5 mmol) and N,N-dimethylformamide (10 mL) were added to a round-bottom flask in sequence, and the air in the tube was quickly replaced with nitrogen three times, and the reaction solution was kept at 80 ° C and stirred for 15 hours. TLC and LC-MS showed that the reaction was complete. After the reaction solution was cooled to room temperature, water (20 mL) was added to quench it and extracted with ethyl acetate (15 mL×3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (eluent: dichloromethane containing 5% methanol) to give compound 8b (388 mg, yield 80%) as a light yellow solid.
[0248] MS(ES + ):m / z 508.2[M+Na] + .
[0249] Step 2: Synthesis of 3-(2-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)ethoxy)propanoic acid (8c)
[0250] Compound 8b (49 mg, 0.1 mmol) was dissolved in formic acid (2 mL) at room temperature, and the reaction solution was stirred at room temperature for 15 hours. TLC and LC-MS showed that the reaction was complete, and the reaction solution was directly concentrated under reduced pressure and separated and purified by Prep-TLC (dichloromethane containing 5% methanol as eluent) to obtain compound 8c (30 mg, yield 70%) as a light yellow solid.
[0251] MS(ES + ):m / z 430.1[M+H] + .
[0252] Step 3: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(3-(2-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)ethoxy)propanoyl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (8)
[0253] 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 29 mg, 0.075 mmol) and N,N-diisopropylethylamine (DIPEA, 13 mg, 0.10 mmol) were added to a solution of compound 8c (21 mg, 0.05 mmol) and compound Int-4 (23 mg, 0.05 mmol) in N,N-dimethylformamide (1 mL) at room temperature, and the reaction solution was stirred at room temperature for 15 hours. TLC and LC-MS showed that the reaction was complete, and water (5 mL) was added to quench, and then extracted with dichloromethane (5 mL×3). The organic phases were combined and concentrated under reduced pressure, and then separated and purified by Prep-HPLC (water containing 30–80% acetonitrile as the mobile phase) to obtain compound 8 (11 mg, yield 26%) as a white solid.
[0254] MS(ES + ):m / z 854.3[M+H] + .
[0255] 1 H NMR (400MHz, DMSO-d6): δ13.93(minor),13.27(major)(s,1H),11.11(s,1H),10.62(minor),10.45(major)(s,1H),8.50(major),8.38(m inor)(s,1H),8.22–8.15(m,1H),8.10(t,J=7.6Hz,1H),8.03(d,J=8.2Hz,1H),7.91(major),7.68(minor)(s,1H),7.39–6.93(m,5H),5.40 (minor),5.32(major)(t,J=4.7Hz,1H),5.06(qn,J=6.7Hz,1H),4.46(minor),4.44(major)(s,2H),4.02–3.94(m,1H),3.76–3.61(m,9H) ,3.59–3.50(m,7H),2.96–2.79(m,2H),2.56(t,J=6.7Hz,2H),2.40–2.32(m,1H),2.07–1.95(m,2H),1.70–1.58(m,2H),1.19–1.03(m,2H).
[0256] Example 9: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(5-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)pent-4-ynyl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (9)
[0257]
[0258] Synthesis route:
[0259]
[0260] Step 1: Synthesis of tert-butyl 5-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)pent-4-ynoate (8b)
[0261] At room temperature, compound lnt-5 (338 mg, 1.0 mmol), bis(triphenylphosphine)palladium(II) dichloride (35 mg, 0.05 mmol), cuprous iodide (10 mg, 0.05 mmol), triethylamine (304 mg, 3.0 mmol), tert-butyl 4-pentynoate 9a (231 mg, 1.5 mmol) and N,N-dimethylformamide (10 mL) were added to a round-bottom flask in sequence, and the air in the tube was quickly replaced with nitrogen three times, and the reaction solution was kept at 80 ° C and stirred for 15 hours. TLC and LC-MS showed that the reaction was complete. After the reaction solution was cooled to room temperature, water (20 mL) was added to quench it and extracted with ethyl acetate (15 mL×3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by silica gel column chromatography (eluent: dichloromethane containing 5% methanol) to give compound 9b (341 mg, yield 83%) as a light yellow solid.
[0262] MS(ES + ):m / z 412.2[M+H] + .
[0263] Step 2: Synthesis of 5-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)pent-4-ynoic acid (9c)
[0264] Compound 9b (82 mg, 0.2 mmol) was dissolved in formic acid (3 mL) at room temperature, and the reaction solution was stirred at room temperature for 15 hours. TLC and LC-MS showed that the reaction was complete, and the reaction solution was directly concentrated under reduced pressure and separated and purified by Prep-TLC (dichloromethane containing 10% methanol as eluent) to obtain compound 9c (43 mg, yield 61%) as a light yellow solid.
[0265] MS(ES + ):m / z 356.1[M+H] + .
[0266] Step 3: Synthesis of N-(3-(difluoromethyl)-1-(1-(1-(5-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)pent-4-ynyl)piperidin-4-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (9)
[0267] 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 29 mg, 0.075 mmol) and N,N-diisopropylethylamine (DIPEA, 13 mg, 0.10 mmol) were added to a solution of compound 9c (18 mg, 0.05 mmol) and compound Int-4 (23 mg, 0.05 mmol) in N,N-dimethylformamide (1 mL) at room temperature, and the reaction solution was stirred at room temperature for 15 hours. TLC and LC-MS showed that the reaction was complete, and water (5 mL) was added to quench, and then extracted with dichloromethane (5 mL×3). The organic phases were combined and concentrated under reduced pressure, and then separated and purified by Prep-HPLC (water containing 30–80% acetonitrile as the mobile phase) to obtain compound 9 (7 mg, yield 18%) as a white solid.
[0268] MS(ES + ):m / z 780.3[M+H] + .
[0269] 1H NMR (400MHz, DMSO-d6): δ13.84(minor),13.23(major)(s,1H),11.11(minor),10.99(major)(s,1H),10.47(s,1H),8. 54(major),8.34(minor)(s,1H),8.25–8.14(m,1H),8.11(t,J=8.1Hz,1H),8.03(d,J=8.4Hz,1H),7.91(major),7.69(m inor)(s,1H),7.40–6.89(m,5H),5.40–5.10(m,2H),4.17–4.05(m,2H),3.88–3.76(m,2H),3.62–3.59(m,2H),3.54(s, 3H),3.15–3.08(m,2H),2.94–2.83(m,2H),2.72–2.63(m,6H),2.06–1.97(m,1H),1.84–1.68(m,2H),1.21–1.05(m,2H).
[0270] Example 10: Synthesis of N-(3-(difluoromethyl)-1-(1-(6-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)hex-5-yn-1-yl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (10)
[0271]
[0272] Synthesis route:
[0273]
[0274] The synthetic route and method are the same as those of Example 5, except that the compound Int-4 in step 3 is replaced by an equivalent amount of compound Int-6, to obtain compound 10 as a white solid.
[0275] MS(ES + ):m / z 697.3[M+H] + .
[0276] 1H NMR (400MHz, DMSO-d6): δ13.85(minor),13.24(major)(s,1H),11.11(minor),11.00(major)(s,1H),10.58( minor),10.46(major)(s,1H),8.51(major),8.28(minor)(s,1H),8.23–8.16(m,1H),8.10(t,J=7.6Hz,1H), 8.03 (d, J = 8.2 Hz, 1H), 7.91(major), 7.69 (minor) (s, 1H), 7.41 – 6.89 (m, 5H), 5.37 (minor), 5.32(major)(t,J=4.6Hz,1H),5.08(qn,J=6.6Hz,1H),3.70(t,J=7.0Hz,2H),3.65(s,1H),3.58(s,3H),3.5 1(s,1H),2.54(t,J=6.9Hz,2H),2.02–1.97(m,3H),1.64–1.58(m,2H),1.52–1.43(m,3H),1.35–1.29(m,2H).
[0277] Example 11: Synthesis of N-(3-(difluoromethyl)-1-(1-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-3-oxopropoxy)ethyl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (11)
[0278]
[0279] Synthesis route:
[0280]
[0281] The synthetic route and method are the same as those of Example 7, except that the compound Int-4 in step 2 is replaced by an equivalent amount of compound Int-6, to obtain compound 11 as a white solid.
[0282] MS(ES + ):m / z 717.3[M+H] + .
[0283] 1H NMR (400MHz, DMSO-d6): δ11.02(s,1H),10.49(s,1H),9.87(s,1H),8.40(s,1H),8.21(s,1H),8.17(d,J=7.8Hz,1 H),8.11(t,J=7.7Hz,1H),8.03(d,J=7.5Hz,1H),7.83(s,1H),7.78(d,J=7.0Hz,1H),7.51–7.44(m,2H),7.22(t, J=54.1Hz,1H),7.02(d,J=1.9Hz,1H),5.13(dd,J=13.3,5.0Hz,1H),5.03(qn,J=6.5Hz,1H),4.41–4.30(m,2H),3 .73–3.68(m,4H),3.58–3.56(m,4H),2.95–2.86(m,1H),2.68–2.58(m,4H),2.38–2.27(m,1H),2.06–1.94(m,2H).
[0284] Example 12: Synthesis of N-(3-(difluoromethyl)-1-(1-(3-(2-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)ethoxy)propanoyl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (12)
[0285]
[0286] Synthesis route:
[0287]
[0288] The synthetic route and method are the same as those of Example 8, except that the compound Int-4 in step 3 is replaced by an equivalent amount of compound Int-6, to obtain compound 12 as a white solid.
[0289] MS(ES + ):m / z 771.4[M+H] + .
[0290] 1H NMR (400MHz, DMSO-d6): δ13.85(minor),13.24(major)(s,1H),11.11(s,1H),10.48(major),10.42(minor)(s,1H),8.51(majo r),8.35(minor)(s,1H),8.22–8.14(m,1H),8.10(t,J=7.5Hz,1H),8.03(d,J=8.0Hz,1H),7.90(major),7.69(minor)(s,1H),7 .44–6.92(m,5H),5.38(major),5.32(minor)(dd,J=12.5,5.5Hz,1H),4.63(t,J=8.4Hz,1H),4.48–4.41(m,3H),4.34(t,J=9.1 Hz,1H),4.16–4.12(m,1H),3.67–3.61(m,6H),3.60–3.54(m,4H),2.95–2.55(m,2H),2.38(t,J=6.3Hz,2H),2.07–1.94(m,2H).
[0291] Example 13: Synthesis of N-(3-(difluoromethyl)-1-(1-(5-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)pent-4-ynyl)azetidin-3-yl)-1H-pyrazol-4-yl)-6-(1H-pyrazol-3-yl)picolinamide (13)
[0292]
[0293] Synthesis route:
[0294]
[0295] The synthetic route and method are the same as those of Example 9, except that the compound Int-4 in step 3 is replaced by an equivalent amount of compound Int-6, to obtain compound 13 as a white solid.
[0296] MS(ES + ):m / z 697.2[M+H] + .
[0297] 1H NMR (400MHz, DMSO-d6): δ11.11(s,1H),10.49(s,1H),8.49(s,1H),8.18(d,J=7.6Hz, 1H),8.11(t,J=7.7Hz,1H),8.04(d,J=7.4Hz,1H),7.84(s,1H),7.39–6.93(m,5H),5. 47–5.31(m,2H),4.66(t,J=8.4Hz,1H),4.50–4.47(m,1H),4.37(t,J=9.1Hz,1H),4.2 2–4.16(m,1H),3.66(s,3H),2.96–2.84(m,2H),2.76–2.59(m,4H),2.06–1.95(m,2H).
[0298] Compounds 14-25 were synthesized according to the above examples.
[0299] Biological Detection 1. ADP-Glo Detection of IRAK1 and IRAK4 Kinase Activity
[0300] Use kinase reaction buffer (50 mM Hepes, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, H2O) to prepare 2× ATP / substrate solution and 2× kinase solution, Use a 655T sonic pipette to transfer 40Nal of the compound dilution to a 384 assay plate. After centrifugation, add 2μL of 2× kinase solution, centrifuge at 1000rpm for one minute, and incubate at 25°C for 10 minutes. Then add 2μL of 2× ATP / substrate solution to the 384 assay plate, centrifuge at 1000rpm for one minute, and incubate at 25°C for 60 minutes. Add 4μL of ADP-Glo reagent to each well, centrifuge at 1000rpm for one minute, and incubate at 25°C for 40 minutes. Add 8μL of kinase assay reagent to each well, centrifuge at 1000rpm for one minute, and incubate at 25°C for 40 minutes. Read the chemiluminescent signal with a BMG microplate reader and calculate the kinase activity inhibition rate according to the following formula:
[0301] Inhibition rate % = (average value of positive control wells - average value of compound wells) / (average value of positive control wells - average value of negative control wells) × 100
[0302] The half-maximal inhibitory concentration (IC50) of the compound on enzyme activity was obtained by fitting the nonlinear fitting formula (doseresponse-variable slope) in GraphPad 8.0.
[0303] Nonlinear fitting formula: Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC 50-X)×HillSlope))
[0304] X: Logarithm of compound concentration
[0305] Y: inhibition rate %;
[0306] HillSlope: The slope of the curve.
[0307] Bottom: The Y value of the bottom platform.
[0308] Top: Y value of the top platform.
[0309] Table 1 below provides the IC50 ranges of some compounds for inhibiting the kinase activities of IRAK1 and IRAK4: A: <1 nM; B: 1-10 nM; C: >10 nM.
[0310] Table 1 Inhibition of IRAK1 and IRAK4 kinase activity by compounds
[0311]
[0312] Biological Assay 2. Degradation of IRAK4 in Cells
[0313] The cell line THP-1 used in the experiment was purchased from Wuhan Pronocell Life Science Co., Ltd. and cultured in RPMI-1640 (0.05 mM β-mercaptoethanol and 1% P / S) containing 10% fetal bovine serum. Cells in the logarithmic phase were collected by centrifugation, resuspended in culture medium, counted, and the cell density was adjusted to 1×10 6 / mL, 2mL was inoculated into each well and cultured in a 37°C, 5% CO2 incubator for 30 minutes. For the degradation of IRAK4 in THP-1 cells, the 20mM compound stock solution was diluted with DMSO to 10000μM, 5000μM, 1000μM, 200μM, 40μM, 8μM, 1.6μM, 0.32μM, and 0.064μM. 2μL was added to each well to the corresponding concentration wells, and the final concentrations were 20μM, 10μM, 5μM, 1μM, 200nM, 40nM, 8nM, 1.6nM, 0.32nM, and 0.064nM, respectively, and cultured in a 37°C, 5% CO2 incubator for 24 hours. After treating cells with the corresponding concentration of compounds for 24 hours, the cells were collected by centrifugation and the supernatant was discarded. The cell pellet was lysed on ice with RIPA lysis buffer (protease inhibitor) for 15 minutes, centrifuged at 4°C and 13,000 rpm for 30 minutes, and the supernatant was collected. The protein concentration was measured and adjusted to 3 mg / mL. 5× SDS-PAGE loading buffer was added and heated at 95°C for 7 minutes. Bio-Rad Mini-PROTEAN Tetra was used for SDS-PAGE electrophoresis and LI-COR Odyssey's dual-color infrared fluorescence gel imaging system was used to image the protein of IRAK4 in the sample. Image J was used for semi-quantification to calculate the degradation rate of IRAK4 by the compound.
[0314] Band strength' = Band strength IRAK4 / Band Strength GAPDH
[0315] Degradation rate % = (1-band intensity' 化合物 / Band intensity' DMSO )×100
[0316] Where GAPDH stands for glyceraldehyde-3-phosphate dehydrogenase.
[0317] Figure 1 A schematic diagram of IRAK4 degradation by some compounds in THP-1 cells is provided. Figure 1 ( Figure 1 The mark "—" in the last column indicates a negative control, and in the figure, there are two concentrations of 1.6 nM and 8 nM in compound 3 that were added in reverse during the experimental operation, which have been additionally marked with red letters in a red frame). It can be seen that compounds 2-6 and 8-10 have a significant degradation effect on IRAK4 in THP-1 cells and show a Hook effect at high concentrations.
[0318] Table 2 below provides the DC50 ranges of some compounds for IRAK4 degradation in THP-1 cells: A: <1 nM; B: 1-10 nM; C: 11-100 nM; D: 101-1000 nM; E: >1000 nM.
[0319] Table 2 Concentration-degradation of compounds on IRAK4 in THP-1
[0320]
[0321] Biological assay 3. Effects on the secretion of TNF-α and IL-6 by human PBMCs
[0322] The human PBMCs used in the experiment were purchased from Miaoshun (Shanghai) Biotechnology Co., Ltd., with the donor number DS232998. After the cryopreserved human PBMCs were revived, they were immediately resuspended in RPMI-1640 (2% FBS and 1% P / S), counted, and the cell density was adjusted to 5×10 5 / mL, 90uL per well was inoculated in a 96-well U-shaped plate and placed in a 37°C, 5% CO2 incubator for 30 minutes. Take 0.5μL of 10mM compound DMSO stock solution and add 49.5μL RPMI-1640 (2% FBS and 1% P / S) to dilute to 100μM working solution, then dilute five times with RPMI-1640 (2% FBS and 1% P / S), take 0.5μL DMSO and add 49.5μL RPMI-1640 (2% FBS and 1% P / S) as the working solution of the DMSO control well. Take 10μL of compound working solution and DMSO working solution and add them to the corresponding cell wells, centrifuge at 600rpm for 30 seconds, and place in a 37°C, 5% CO2 incubator overnight. LPS was diluted to a working concentration of 2.5 μg / mL with RPMI-1640 (2% FBS and 1% P / S), and 25 μL of LPS working solution was added to each well of the corresponding well, centrifuged at 600 rpm for 30 seconds, and placed in a 37°C, 5% CO2 incubator for 4-6 hours (hTNF-α) or 24 hours (hIL-6). After the incubation time, centrifuged at 1000 rpm for 5 minutes, and the supernatant was taken and stored in another 96-well plate. The supernatant was diluted three times for ELISA analysis of hTNF-α and hIL-6, and the concentrations of hTNF-α and hIL-6 in the supernatant of the corresponding experimental wells were calculated according to the instructions of the ELISA kit. According to the following formula, the inhibition of the compound on the secretion of hTNF-α and hIL-6 by human PBMCs stimulated by LPS was calculated.
[0323] Inhibition rate % = (1-(compound well-background well) / (negative control well-background well)) × 100
[0324] Compound wells: cells + compound + LPS stimulation
[0325] Background wells: cells + DMSO control
[0326] Negative control wells: cells + DMSO control + LPS stimulation
[0327] Table 3 below provides the IC50 ranges of some compounds for the inhibition of hTNF-α and hIL-6 secretion by human PBMCs stimulated by LPS: A: <1 nM; B: 1-10 nM; C: 11-100 nM; D: 101-1000 nM; E: >1000 nM.
[0328] Table 3 Inhibition of hTNF-α and hIL-6 secretion by compounds in human PBMCs stimulated by LPS
[0329]
[0330] Biological detection 4. Effects on TLR signaling pathway
[0331] The cell line THP-1 used in the experiment was purchased from Wuhan Punosai Life Science Co., Ltd. and cultured with RPMI-1640 (0.05mMβ-mercaptoethanol and 1% P / S) containing 10% fetal bovine serum. The cells in the logarithmic phase were collected by centrifugation, resuspended with culture medium, counted, and the cell density was adjusted to 1×10^6 / mL. 4mL was inoculated into each well and placed in a 37°C, 5% CO2 incubator for 30 minutes. The 10mM compound stock solution was diluted with DMSO to 1000μM, 100μM, 10μM, 1μM, 0.1μM, and 0.01μM. 4μL was added to each well to the corresponding concentration wells, and the final concentrations were 1000nM, 100nM, 10nM, 1nM, 0.1nM, and 0.01nM, respectively, and placed in a 37°C, 5% CO2 incubator for 24 hours. After 24 hours, 20 μL / well 1 mg / mL LPS was added to the corresponding wells and placed in a 37°C, 5% CO2 incubator for 30 minutes. After 30 minutes, the cells were collected by centrifugation and the supernatant was discarded. The cell pellet was lysed on ice with RIPA lysis buffer (protease inhibitors and phosphatase inhibitors) for 15 minutes, centrifuged at 4°C and 13000rpm for 30 minutes, the supernatant was collected, the protein concentration was measured, the protein concentration was adjusted to 4 mg / mL, 5×SDS-PAGE loading buffer was added, and the samples were heated at 95°C for 7 minutes. The protein content of Phospho-p38 MAPK (Thr180 / Tyr182), Phospho-ERK1 / 2 (Thr202 / Tyr204) and NF-κB p65 Phospho (Ser529) in the samples was detected by SDS-PAGE and WB.
[0332] Test results such as Figure 2 As shown, from Figure 2 It can be seen that compound 2, which can degrade IRAK4, can inhibit the MAPK and NFκB signaling pathways downstream of TLR / IL1R.
[0333] The applicant declares that the present invention illustrates the protein degradation targeting chimeric molecule and its application through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of the raw materials selected by the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
Claims
1. A protein degradation targeting chimeric molecule or its mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, characterized in that: The protein degradation targeting chimeric molecule has a structure shown in formula (I): Among them, R f is selected from halogen or C1-C3 alkyl, wherein the C1-C3 alkyl is unsubstituted or substituted by a deuterium atom and / or a halogen atom; Ring A and Ring B are each independently absent or a 4-10 membered cycloalkyl or heterocyclic group, and contain 0-2 heteroatoms independently selected from N, O and S, and the cycloalkyl or heterocyclic group is substituted or unsubstituted, and when substituted, the substituents are independently selected from one or at least two of a deuterium atom, a halogen, an amino group, a hydroxyl group, a thiol group, a nitro group, a cyano group, a carbonyl group, a carboxyl group, an ester group, an alkenyl group, an alkynyl group, an alkyl group, an alkoxy group, a hydroxyalkyl group, an alkylthio group, an alkylamino group, a cycloalkyl group, a heterocyclic group, a cycloalkyloxy group, a cycloalkylthio group, a heterocycloalkyloxy group, a heterocycloalkylthio group, an aryl group or a heteroaryl group; LBM is the E3 ubiquitin ligase binding moiety; L is selected from C1-C 20 Alkyl, or C1-C 20 0, 1, 2, 3, 4, 5 or 6 -CH2- on the alkyl group are optionally replaced by one or at least two of the following atoms or groups: -O-, -S-, -NR a -, carbonyl, alkenyl, alkynyl, -C(O)R a -、-O(O)CR a -、-C(O)OR a -、-C(O)NR a -、-NHC(O)R a -、-S(O)R a -、-S(O)2R a -、-S(O)NR a -、-S(O)2NR a -、-NHS(O)R a -、-NHS(O)2R a -、-P(O)R a -、-P(O)NR a -, aryl, heteroaryl, cycloalkyl, heterocyclic radical, wherein the carbonyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic radical is optionally substituted by one or at least two groups selected from deuterium atom, halogen, amino, hydroxyl, mercapto, nitro, cyano, carbonyl, carboxyl, ester group, alkenyl, alkynyl, alkyl, alkoxy, hydroxyalkyl, alkylthio, alkylamino, cycloalkyl, heterocyclic radical, cycloalkyloxy, cycloalkylthio, heterocycloalkyloxy, heterocycloalkylthio, aryl and heteroaryl; wherein R a R is independently selected from H, D, halogen, amino, hydroxyl, mercapto, nitro, cyano, carbonyl, carboxyl, ester, alkenyl, alkynyl, alkyl, alkoxy, cycloalkyl, heterocyclic radical, aryl, heteroaryl, wherein the alkenyl, alkynyl, alkyl, alkoxy, cycloalkyl, heterocyclic radical, aryl and heteroaryl are optionally substituted with one or at least two groups selected from deuterium atom, halogen, amino, hydroxyl, mercapto, nitro, cyano, carbonyl, carboxyl, ester, alkenyl, alkynyl, alkyl, alkoxy, cycloalkyl, heterocyclic radical, aryl and heteroaryl; or R a Together with the atoms to which they are attached, they form a cycloalkyl or heterocyclic group, which is optionally substituted by one or at least two groups selected from a deuterium atom, a halogen, an amino group, a hydroxyl group, a mercapto group, a nitro group, a cyano group, a carbonyl group, a carboxyl group, an ester group, an alkenyl group, an alkynyl group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group.
2. The protein degradation targeting chimeric molecule according to claim 1, or its mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, characterized in that: R f Selected from -CF2CF3, -CF3, -CH3, -CD3, -CF2H, -CF2D, -CFH2 or -CFD2; Preferably, the LBM is selected from any one or at least two E3 ubiquitin ligase ligands of CRBN, VHL, IAP or MDM2; preferably, the LBM is selected from any one of the following groups: The wavy line represents the attachment site of the group.
3. The protein degradation targeting chimeric molecule according to claim 1 or 2, or its mesoform, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, characterized in that: L is selected from any one of the following groups: x, y and z are each independently 0, 1, 2, 3, 4, 5, 6, 7 or 8, and the wavy line represents the attachment site of the group.
4. The protein degradation targeting chimeric molecule according to any one of claims 1 to 3, or its mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, characterized in that: L is selected from L15 or L16 as follows: Wherein, preferably, x and y are each independently 0, 1, 2, 3, 4 or 5, and the wavy line represents the connection site of the group.
5. The protein degradation targeting chimeric molecule according to any one of claims 1 to 4, or its mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, characterized in that: The protein degradation targeting chimeric molecule is a compound represented by the general formula (II): Among them, R f , L and LBM are as defined in the general formula (I) as claimed in claim 1; Preferably, the protein degradation targeting chimeric molecule is a compound represented by general formula (III): Among them, R f , L and LBM are as defined in the general formula (I) as claimed in claim 1.
6. The protein degradation targeting chimeric molecule according to any one of claims 1 to 4, or its mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, characterized in that: The protein degradation targeting chimeric molecule is any one of the following compounds 1-25:
7. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the protein degradation targeting chimeric molecule according to any one of claims 1 to 6 or its mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.
8. Use of the protein degradation targeting chimeric molecule according to any one of claims 1 to 6, or its racemate, racemate, enantiomer, diastereomer, or mixture thereof, or its pharmaceutically acceptable salt, or the pharmaceutical composition according to claim 7 in the preparation of a medicament for treating and / or preventing a disease or condition associated with IRAK kinase activity.
9. The use according to claim 8, characterized in that: The disease or disorder associated with IRAK kinase activity is selected from cancer, neurodegenerative disease, autoimmune disease, inflammatory disease, viral disease, cardiovascular disorder, kidney disease, liver disease, metabolic disorder, genetic disorder or proliferative disorder.
10. The use according to claim 9, characterized in that: The cancer is selected from the group consisting of breast cancer, small cell lung cancer, non-small cell lung cancer, bronchoalveolar cancer, prostate cancer, bile duct cancer, bone cancer, bladder cancer, head and neck cancer, kidney cancer, liver cancer, gastrointestinal tissue cancer, esophageal cancer, ovarian cancer, pancreatic cancer, skin cancer, testicular cancer, thyroid cancer, uterine cancer, cervical and vaginal cancer, leukemia, multiple myeloma or lymphoma; Preferably, the autoimmune disease and inflammatory disease are selected from systemic lupus erythematosus, lupus nephritis, arthritis, psoriasis, Crohn's disease, atopic dermatitis, gout, protein-related periodic syndrome, chronic kidney disease or acute kidney injury, chronic obstructive pulmonary disease, asthma, bronchospasm or graft-versus-host disease.
Citation Information
Patent Citations
Bifunctional protein degradation targeting chimera compound as well as preparation method and medical application thereof
CN114341128A
Indazole derivative as well as preparation method and application thereof
CN115244042A
Targeted IRAK4 protein degradation compound and application thereof
CN117164583A
CRBN ligands and uses thereof
US20200377469A1
Pyrazole compounds, pharmaceutical compositions thereof and use thereof
US20210340124A1
Cited By
Interleukin receptor-associated kinase (IRAK) protac degraders and medical use thereof
WO2025217094A1
